Stay Curious. Stay Connected.
MailNewsletters♡Donate Now
Sign up
*Password must be at least 8 characters and contain one uppercase letter, one lowercase letter, one number and one symbol.
Already have an account?
By submitting, you consent that you are at least 18 years of age and to receive information about MPR's or APMG entities' programs and offerings. The personally identifying information you provide will not be sold, shared, or used for purposes other than to communicate with you about MPR, APMG entities, and its sponsors. You may opt-out at any time clicking the unsubscribe link at the bottom of any email communication. View our Privacy Policy.
Sign in to your profile
Forgot Password?
New to MPR News?
Welcome back
to news
for you
Reset Password

Enter the username on file and we'll send you a code to reset your password.

Still require assistance or not sure what your User Name is?
Welcome back
to news
for you
Email Verification

A verification code has been emailed to

Still awaiting the code?
Martin Moylan
St. Paul, Minn.

Deal boosts St. Jude Medical in pain treatment therapy

Go Deeper.

Create an account or log in to save stories.

Log inCreate a free Account

Like this?

Thanks for liking this story! We have added it to a list of your favorite stories.

Show me!

St. Jude Medical will pay $200 million for a Massachusetts company's whose products treat chronic pain.

NeuroTherm's main product treats spinal pain with the pinpoint application of heat, destroying nerves sending pain signals from the neck or back, Little Canada-based-St. Jude said in a statement.

Pain management accounts for a relatively small part of St. Jude's $5.5 billion in annual sales. But the potential market for chronic pain management is huge, with an estimated 1.5 billion people worldwide needing relief, said Debbie Wong, an analyst with the investment research firm Morningstar.

Neurostimulation works by blocking pain messages before they get to the brain. Another Minnesota company, Medtronic, is a heavy hitter in neurostimulation, but there is a lot of room for improvement of existing pain therapies, Wang said.